You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東陽光藥(01558.HK)擬20.57億元向廣東東陽光藥業收購兩種醫藥產品資產
格隆匯 11-13 19:51

格隆匯11月13日丨東陽光藥(01558.HK)公佈,於2019年11月13日,公司與廣東東陽光藥業訂立購買協議,據此,公司同意收購目標資產,總代價為人民幣20.57億元。

據悉,廣東東陽光藥業(即宜昌東陽光藥研發有限公司的附屬公司)為東陽光藥研發集團成員公司,東陽光藥研發集團為中國領先的藥物研究機構之一,擁有超過1,600名研究人員,其中包括納入中國政府國家千人計劃及青年領軍人物的專家。廣東東陽光藥業亦獲國家人力資源和社會保障部及全國博士後管委會認可為博士後科研工作站。

目標資產指與目標產品及其在中國境內所應附有的全部權益、利益及依法享有的全部權利。目標產品指兩種產品,包括焦穀氨酸榮格列淨和利拉魯肽。

於本公告日期,母公司廣東東陽光科技控股股份有限公司直接持有該公司約50.40%股權,因此為該公司的控股股東。深圳東陽光實業直接及間接持有母公司約53.32%股權,其中約27.97%股權為直接持有,而廣東東陽光藥業為深圳東陽光實業的間接非全資附屬公司。

公司稱,公司已決定自廣東東陽光藥業收購目標產品,原因如下:(i)目標產品具有獨特的藥理機制,且在目前國內市場中佔據領先的競爭位置,擁有巨大的市場潛力;(ii)目標產品的擬用適應症契合公司現有產品線,待日後若成功獲批上市,將與該公司現有產品線形成協同效應,有望快速進入市場並形成可觀銷售額;(iii)目標產品將擴大該公司的產品組合,待日後若成功獲批上市,將進一步提升該公司的綜合實力及改善公司的收入結構,而這與該公司的長期發展策略一致;及(iv)透過有關收購,可避免該公司投放大量資源於藥物研發,並降低研發失敗的風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account